Sugi Predict

Sugi Predict / Compounds / SCHEMBL3528228

SCHEMBL3528228

SCHEMBL3528228

COC(=O)CCCC#Cc1cc(Cl)ccc1[N+](=O)[O-]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ PKM P14618 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ TDP1 Q9NUW8 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ BACE1 P56817 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ PDE7A Q13946 1/20 0.38
▸ TXNRD1 Q16881 1/20 0.38
▸ G6PD P11413 1/20 0.38
▸ CRHBP P24387 1/20 0.38
▸ CRHR2 Q13324 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ PSMD14 O00487 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ BLM P54132 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3523873 0.97 MAPT (0.43) MAPTL3MBTL1PKMLMNATDP1
SCHEMBL3528411 0.93 L3MBTL1 (0.45) MAPTL3MBTL1PKMLMNATDP1
SCHEMBL3525140 0.82 SLC10A2 (0.42) MAPTL3MBTL1PKMLMNAALDH1A1
SCHEMBL4878167 0.81 MAPT (0.53) MAPTPKMLMNAALDH1A1SMN1; SMN2
SCHEMBL3528298 0.81 MAPT (0.47) MAPTL3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL3527495 0.77 MAPT (0.46) MAPTL3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL4659391 0.77 MAPT (0.48) MAPTL3MBTL1PKMLMNATDP1
SCHEMBL12850045 0.76 MAPT (0.41) MAPTL3MBTL1MEN1KMT2A
SCHEMBL3526484 0.75 LMNA (0.45) MAPTLMNATDP1ALDH1A1SMN1; SMN2
SCHEMBL3525068 0.75 LMNA (0.51) MAPTLMNAALDH1A1TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109316601-B Pharmaceutical composition and use thereof 武汉朗来科技发展有限公司 2021-11-09 — — CN disclosed
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 — — US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 — — US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 — — US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP MAPT 214/4885L3MBTL1 4230/4885PKM 728/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG MAPT 730/4885L3MBTL1 4531/4885PKM 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.